Diagnostic HYBRIDS Announces Release of Super E-Mix(R) ReadyCells(R)
Diagnostic HYBRIDS announces the release of its patented Super E-Mix cell line for enterovirus culture in the frozen ReadyCells® format. The availability of Super E-Mix in this novel format allows even the smallest clinical laboratory to offer the sensitivity and speed of rapid cell culture for diagnosis of enteroviral infection. The ReadyCells are provided as confluent monolayers in shell vials and stored frozen at -70°C for up to six months, allowing laboratories to keep the cells from a single production lot available while minimizing cell waste. Cells are thawed as needed to meet daily specimen volumes and ready to inoculate with clinical specimen in four minutes with Diagnostic HYBRIDS’ specialized ReadyCells heat block.
According to Patricia Harris, Executive Director of Worldwide Sales for Diagnostic HYBRIDS, “The ReadyCells platform was successfully launched in June 2002 with an initial release of R-Mix®, Hs27 and McCoy ReadyCells. These products have enabled clinical laboratories to perform cell culture for a large number of respiratory viruses including Influenza and RSV, herpes viruses including HSV-1, HSV-2, CMV and VZV, and other sexually transmitted diseases such as Chlamydia. The addition of Super E-Mix further empowers these laboratories to offer their patients the highest quality result in the shortest timeframe possible.”
ReadyCells provides flexibility to all virus culture labs. Large users gain benefit when test volume exceeds expectations, and the frozen inventory helps eliminate weekly shipping costs for smaller volume laboratories. International customers benefit from access to patented cell systems like R-Mix and Super E-Mix that otherwise would not be possible due to extreme shipping stress. In all cases, ReadyCells remain frozen and useful until the user needs them.
Super E-Mix ReadyCells complement the Diagnostic HYBRIDS enterovirus detection products, which include patented Flocked Swabs for specimen collection, Universal Transport Medium for specimen transport, and the recently introduced D3® IFA Enterovirus Identification Kit.
About Diagnostic HYBRIDS
Diagnostic HYBRIDS invents, develops, manufactures, and sells innovative diagnostic and analytical products for a wide range of viral respiratory diseases, herpes virus infections, and other specific viral and thyroid diseases. The company also develops and commercializes innovative and genetically engineered cell-based detection products for the pharmaceutical and biotechnology industry, with an initial focus on pharmacology assays and products that measure drug clearance and anti-viral interventions with drugs and vaccines. The company is certified to ISO 13485 standards and manufactures live continuous and primary cell cultures for clinical diagnostics and pharmacology assays from its headquarters in Athens, OH. Diagnostic HYBRIDS was named one of the 500 Fastest Growing Companies in America in 2004 and 2005 by Inc. Magazine. The company is a pillar member of Bio-Ohio, a statewide organization of bioscience companies accelerating the bioscience and healthcare economy in Ohio. For more information, please visit www.dhiusa.com.